How to Actually Tackle Life Science Consulting Cases Without Looking Like You Winged It
The first thing you need to understand is that Life Science Consulting Cases are not generic business cases with a healthcare skin applied over them. The difference between a candidate who gets it and one who doesn't comes down to whether they can think in regulatory pathways, indication-level market dynamics, and reimbursement windows instead of just drawing a standard market sizing triangle. Most firms — McKinsey, BCG, Bain, LEK, ZS — structure these around either a therapeutic area deep-dive or a commercial access problem. You will see cases on biosimilar entry strategy, oncology portfolio prioritization, orphan drug market sizing, CRO selection frameworks, and health economic modeling for novel indications. The structure you use changes dramatically depending on which one lands in front of you. Interviewers are not looking for you to recall a framework from a YouTube video. They are checking whether you can identify the relevant constraints of the life sciences ecosystem without being told. A typical opening prompt might be: "A mid-stage biotech is considering entering the US market for a new PD-L1 inhibitor. Should they pursue accelerated approval or full approval?" A generic candidate immediately starts sizing the PD-L1 inhibitor market. A competent candidate asks about the mechanism of action, the comparator landscape, the patient eligibility criteria, and the PDCO opinion timeline under EMA before doing any math. The order matters. Get it wrong and the rest of the case goes sideways because you are solving the wrong problem with correct arithmetic. Here is the practical workflow I use when working through these cases, whether I am coaching someone or running the analysis myself. Start by mapping the value chain for the specific indication. That means patient journey — from symptom onset to diagnosis, to line of therapy, to treatment discontinuation. Then layer in the regulatory and reimbursement barriers at each step. Then assess the competitive architecture including standard of care, pipeline competitors, and payer formulary position. Only after those three layers are sketched do I pull data. This sequence takes roughly 8 to 12 minutes in a 30-minute case and prevents the common error of jumping straight into revenue projections that ignore access friction.
For market sizing inside life sciences cases, the top-down approach rarely works unless you have solid epidemiology data. The bottom-up approach is more reliable but requires assumptions about prevalence, treatment rate, line of therapy positioning, and price. A realistic assumption set for a rare disease product in the US might look like this: prevalence of 1 in 50,000, diagnosed population of 6,000, treatment rate of 70 percent, average annual treatment cost of $180,000, resulting in a $756 million addressable market. These numbers are illustrative but the structure is what matters. I have seen candidates round prevalence to 1 in 100,000 and then proceed confidently, producing a market size that was half the actual figure. The math was internally consistent but the input was broken. That is the kind of error that shows up on a resume as a red flag during the actual case conversation.
The Hidden Layer: Regulatory and Reimbursement Architecture
This is where most candidates lose points. Life Science Consulting Cases require you to factor in regulatory status as a first-class variable, not an afterthought. Accelerated approval changes the commercial timeline by 18 to 24 months compared to full approval. Orphan drug designation provides seven years of market exclusivity in the US and a ten-year maximum period in the EU under certain conditions. Breakthrough therapy designation can shave time off the review clock but does not guarantee approval. Each of these elements shifts the NPV calculation of a go-to-market strategy and the candidate needs to know which levers exist and when they apply. Reimbursement is equally critical and almost always mishandled. In the US, you are dealing with PBM negotiations, specialty tier placement, and co-pay assistance programs. In the EU, you face national health technology assessment bodies that evaluate clinical value relative to existing treatments. A candidate who states "the drug will be reimbursed" without specifying the mechanism has effectively admitted they do not understand the commercial reality. I once worked through a case where the proposed pricing strategy assumed 90 percent formulary coverage across all major European markets. The actual HTA opinions from the two largest markets — Germany and the UK — recommended conditional reimbursement with strict patient selection criteria, which cut the effective patient population by nearly 60 percent. The initial revenue model was off by a factor of three because the candidate treated reimbursement as a binary yes-or-no question rather than a negotiated outcome shaped by clinical benefit and budget impact.
Get the Full Details
A Real Worked Scenario From a Live Engagement
Let me walk through a concrete example that came up recently. A client — a mid-cap biopharma company — wanted to evaluate whether to pursue a label expansion for their oncology asset into a second-line indication. The standard framework would be: size the second-line market, assess competitive landscape, evaluate clinical benefit, model the financial return. That is correct but incomplete. The missing piece was pharmacoeconomic positioning. Their first-line indication already faced a well-established comparator with a strong safety profile. Entering as a second-line option meant competing against a drug that had established responder rates and a clear place in guideline. The clinical trial data for the second-line indication showed a modest progression-free survival advantage but no overall survival benefit. From a reimbursement perspective, that translates to a high likelihood of a restrictive coverage decision with required biomarker testing, which limits the eligible population further. The workaround I recommended was to reframe the case around health technology assessment positioning rather than pure market sizing. We built a budget impact model that incorporated the biomarker prevalence, the expected adherence rate, and the counterfactual spending under current standard of care. This revealed that even with a favorable clinical profile, the budget impact would exceed typical national threshold levels in three of the five key European markets. The recommendation shifted from a blanket label expansion to a targeted launch in markets with more flexible reimbursement criteria and a stronger value narrative. This took about four hours of modeling work and completely changed the strategic recommendation compared to what a standard top-down market sizing approach would have suggested.
Common Mistakes That Sink Candidates
The first mistake is treating every life science case as a market entry case. Not every prompt requires a go-to-market strategy. Some are about M&A evaluation, others about clinical trial design optimization, and some about operational efficiency in manufacturing or clinical operations. Read the prompt twice before choosing your framework. If the interviewer mentions terms like "asset prioritization" or "portfolio optimization," you are likely dealing with a resource allocation problem, not a market sizing problem. The analytical tools are different. The second mistake is ignoring the difference between biological drugs and small molecules in your commercial modeling. Biosimilars face different pricing pressures, interchangeability rules, and substitution policies than small molecule generics. A biosimilar for a monoclonal antibody like adalimumab operates in a market where biosimilar uptake in the US has been slower than in Europe due to state-level substitution laws and pharmacy benefit manager dynamics. Assuming a fast biosimilar penetration curve based on European data will produce an inflated revenue forecast. The typical US biosimilar penetration rate for a high-volume mAb within three years of first-launch is closer to 25 to 35 percent, not the 60 to 70 percent you might see in Germany. Using the European assumption in a US market case is an easy way to appear uninformed. The third mistake is over-relying on published market research reports without pressure-testing the assumptions. A report might state that the global oncology drug market will reach $300 billion by 2028. That number is an aggregate and tells you nothing about the specific indication, the specific geography, or the specific competitive dynamics of your case. Use such reports as directional anchors, not as inputs for your calculations. Always decompose the aggregate into the components that matter for your specific case — indication, region, line of therapy, and molecule type.
Preparation That Actually Works
Reading casebooks helps but only if you read them actively. For each case, do not just study the answer. Identify which life science-specific constraint the case tests — regulatory pathway, reimbursement mechanism, clinical endpoint relevance, or competitive pipeline timing. Then ask yourself what you would have done differently if the case had a different therapeutic area or geographies. This builds pattern recognition across cases rather than memorizing individual answers. The most useful material to review before an interview is a combination of FDA advisory committee meeting transcripts, EMA assessment reports, and NCCN guideline summaries for the therapeutic areas you are most likely to encounter. Oncology cases dominate life science consulting interviews, so having a working knowledge of the major oncology indications — NSCLC, melanoma, hematology malignancies — and their current treatment paradigms will serve you better than any generic framework drill. Spend two hours reviewing the NCCN guidelines for non-small cell lung cancer and you will be better prepared for most oncology cases than someone who spent six hours re-reading a business case handbook. Another practical tip: practice explaining complex clinical concepts to a non-scientist in under two minutes. Interviewers sometimes test whether you can communicate scientific rationale clearly, especially for commercial strategy roles. If you cannot articulate why a particular biomarker matters for patient selection in simple terms, you will struggle to build a credible commercial argument during the case.
When Standard Approaches Fail
Life Science Consulting Cases have genuine limitations as preparation tools. They cannot fully replicate the ambiguity of real-world engagements where data is incomplete, stakeholders have conflicting priorities, and the correct answer is often a range rather than a single number. A case might give you clean prevalence numbers, but in practice you are often working with confidence intervals and subpopulation data that require qualitative judgment. No amount of case practice prepares you for the moment when the interviewer says "the data you have is incomplete — how do you proceed?" The answer is never "I make an assumption and move on." It is about identifying what information would change the recommendation and proposing a structured approach to obtaining it, even if that means a phased go-to-market or a collaborative decision framework with the client. Additionally, the life sciences consulting market has shifted significantly in recent years. Pure strategy work is increasingly complemented by implementation support, particularly around commercial operations, real-world evidence generation, and market access analytics. Cases that reflect this shift are becoming more common at the newer firms and at the implementation-focused teams within the Big Four. Being aware of this trend and demonstrating comfort with both strategic and operational dimensions of a case will set you apart from candidates who only know the textbook approach.
